Fierce Biotech

After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets

Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its ...

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%

This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider ...

Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears

This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings ...

Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease

Maze Therapeutics (NASDAQ:MAZE) outlined positive Phase II results from its open-label HORIZON study evaluating MZE829 in ...
BioSpace

Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data

Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung ...
FierceBiotech

Maze Therapeutics looks to steer lead kidney disease assets through the clinic with $115M series D

Human genetics biotech Maze Therapeutics has navigated the biotech world’s tricky fundraising landscape to land a $115 million series D. The round was co-led by investors Frazier Life Sciences and ...

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad A…

At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients ...